Most annual panels read a handful of numbers (total cholesterol, LDL, HDL and glucose) and call it a cardiovascular assessment. The biomarkers that predict your cardiovascular future, with the strongest evidence behind them, are largely absent from that panel. Nine biomarkers carry the real prognostic weight. Guideline bodies endorse acting on them. Every one of them is a blood draw at a patient service center. This article is the list, with what each one does and why the default panel skips it.
- ApoB counts the atherogenic particles themselves, which makes it a better risk marker than LDL cholesterol.
- Lp(a) is genetically determined, measurable once and actionable through risk reduction even though the particle itself barely responds to lifestyle.
- Fasting insulin rises years before glucose, which makes it the earliest window into insulin resistance.
- hs-CRP links inflammation to cardiovascular risk and moves with sleep, visceral fat and metabolic strain.
- The Biomarker Audit reads all nine every 90 days inside a flat $299 monthly membership and the pharmacy bills any prescription separately at cost.
The nine and what each one does
1. Apolipoprotein B (ApoB). Every atherogenic particle carries exactly one ApoB molecule, so the ApoB count is the particle count. LDL cholesterol measures the cholesterol cargo inside the particles, which varies, which is why two people with the same LDL can carry very different risk. Guideline bodies increasingly treat ApoB as the primary lipid target.
2. Lipoprotein (a) or Lp(a). A genetically determined particle that accelerates atherosclerosis and aortic valve disease. It barely responds to diet or exercise, which is exactly why measuring it once is valuable. A high Lp(a) rewrites the intensity of everything else and it is found in roughly one in five people at levels that change management.
3. Hemoglobin A1c (HbA1c). A three-month average of blood sugar. It moves slower than fasting glucose and it captures the direction of travel, which is what actually predicts progression to diabetes.
4. Fasting insulin. The earliest window into insulin resistance. The pancreas compensates for years before glucose rises and fasting insulin is the line that shows the compensation. By the time fasting glucose moves, the process is well advanced.
5. hs-CRP. High-sensitivity C-reactive protein measures systemic inflammation and inflammation is the bridge between visceral fat, poor sleep and plaque formation. Values persistently above 3.0 mg/L mark a higher-risk inflammatory profile.
6. The standard lipid panel. Triglycerides and HDL in particular. High triglycerides alongside low HDL usually travel with insulin resistance and the pattern is as informative as any single number on it.
7. TSH with reflex to free T4. Thyroid function influences lipids, weight, heart rate and blood pressure. A thyroid drifting at the edge of its range quietly worsens every other line on this list.
8. The comprehensive metabolic panel. Kidney function, liver enzymes and electrolytes. The kidneys sit at the center of blood pressure control and the liver enzymes show the fatty liver that insulin resistance produces before anything else complains.
9. The CBC with differential. Hemoglobin and hematocrit, because anemia presents as fatigue and high hematocrit raises clot risk, including under testosterone therapy. It is the least glamorous line and the most frequently missed diagnosis lives on it.
Why the default panel skips them
The default annual panel is an artifact of the visit, not of the evidence. It is built to fit a ten-minute appointment, an insurance code and a lab contract. ApoB, Lp(a), fasting insulin and hs-CRP each add cost to the order set and each produce findings that require a conversation, which is exactly what the ten-minute visit cannot accommodate. So the panel reports the six numbers that fit the visit and omits the nine that fit the evidence. The gap between those two lists is where preventable cardiovascular disease lives.
How often to read them and why the cadence matters
A single draw answers where you are. A repeated draw answers where you are going and direction is the clinically useful quantity. The Biomarker Audit reads all nine every 90 days, four times a year, which turns the panel from a snapshot into a film. A falling ApoB alongside a falling hs-CRP says a protocol is working. A rising fasting insulin alongside stable glucose says act now, years before the glucose line would have flagged anything. Neither insight is available from an annual draw.
The audits are included in the Cardiometabolic Optimization Membership, one flat $299 per month covering the clinician relationship and the four draws a year, after a single $598 charge at checkout covering the first two months together. From month three the membership is month to month, cancel anytime. Medication, where the panel and the conversation call for it, is billed by the pharmacy separately at pharmacy cost with zero markup. Clinical care is delivered by licensed physicians of Beluga Health, P.A., licensed in all 50 states, working under GoodLife Health's clinical protocols.


Who should run this panel
Anyone with a family history of early heart disease, anyone carrying weight they cannot move, anyone whose annual panel keeps coming back clean while energy and health trend elsewhere and anyone starting hormone or weight-loss therapy who needs a baseline and a monitoring loop. A person with a documented Lp(a) result and a clean ApoB already has the two most important answers and can run a lighter cadence. The panel is a workup and a workup earns its repetition by changing decisions.
Frequently Asked Questions
Which biomarkers best predict cardiovascular risk?
ApoB, Lp(a), HbA1c, fasting insulin, hs-CRP, the standard lipid panel, thyroid function, the metabolic panel and blood counts. ApoB and Lp(a) carry the most prognostic weight and fasting insulin is the earliest marker of the metabolic trajectory.
Why is ApoB better than LDL cholesterol?
Because every atherogenic particle carries one ApoB molecule, the ApoB count is the particle count. LDL cholesterol measures the cargo inside the particles, which varies between people and over time.
How often should these markers be measured?
Every 90 days during active care. Four draws a year show direction, which is the clinically useful quantity and each audit re-reads the panel against the previous one.
Can I get these tests without a membership?
Yes in principle, since each marker can be ordered at a walk-in lab, though a la carte pricing for nine markers four times a year usually exceeds what an inclusive membership costs and the results still need a clinician who reads them against your history.
Does the membership include the medication?
No. The $299 monthly fee covers the clinician relationship and four Biomarker Audits a year. Medication is billed by the pharmacy as a separate charge at pharmacy cost with zero markup.
What is the commitment to start?
A single $598 charge at checkout covers the first two months together, including the intake and the first audit. From month three the cost is $299 a month and you can cancel anytime.
What if a marker comes back abnormal?
The finding is read against your history and the previous audits inside the same relationship and the protocol responds in the same quarter rather than at an appointment a year away.
One last thing
The difference between a snapshot and a film is repetition and the difference between a report and a workup is a clinician who reads the repetition. Nine markers, four draws a year and a relationship that acts on them is the least exotic, most evidence-backed form of prevention available in a blood draw.
Related Guides
- Cardiometabolic optimization: the definitive guide
- What a Biomarker Audit includes
- hs-CRP blood test: what high inflammation means
- NMR lipoprofile test: what advanced lipid panels show
References
- Arnett DK et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease, Circulation, 2019. doi.org/10.1161/CIR.0000000000000678
- Kronenberg F et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement, European Heart Journal, 2022. doi.org/10.1093/eurheartj/ehac165
- American Diabetes Association, Standards of Care in Diabetes. diabetesjournals.org